Toyoaki Hida

Minokamo, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 163 publications

Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC).

Plain language summary of TASUKI-52: A study looking at nivolumab plus platinum chemotherapy and bevacizumab as a combined treatment for people with advanced or recurrent nonsquamous non-small cell lung cancer (NSCLC).

Journal: Future oncology (London, England)

Published: February 05, 2026

Pathophysiology and treatment of leptomeningeal metastases in lung cancer.

Pathophysiology and treatment of leptomeningeal metastases in lung cancer.

Journal: Translational lung cancer research

Published: November 02, 2025

Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.

Four-Year Outcomes for Nivolumab With Chemotherapy and Bevacizumab in Patients With Nonsquamous NSCLC in the TASUKI-52.

Journal: Cancer science

Published: August 15, 2025

Cerebrospinal fluid cytology for the diagnosis of lung cancer brain metastasis: a case report.

Cerebrospinal fluid cytology for the diagnosis of lung cancer brain metastasis: a case report.

Journal: Translational lung cancer research

Published: January 10, 2025

The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review.

The current landscape and prospects of antibody-drug conjugates for lung cancer brain metastases: a narrative review.

Journal: Translational lung cancer research

Published: October 17, 2024

First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.

First-line nivolumab plus platinum chemotherapy and bevacizumab for advanced nonsquamous non-small cell lung cancer: A 3-year follow-up of the phase 3 randomized TASUKI-52 trial.

Journal: Lung cancer (Amsterdam, Netherlands)

Published: August 21, 2024

Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC.

Diversity of TCR repertoire predicts recurrence after CRT followed by durvalumab in patients with NSCLC.

Journal: NPJ precision oncology

Published: May 27, 2024

A rare case report of a primary lung cancer comprising adenocarcinoma and atypical carcinoid tumor, with the carcinoid component harboring EML4-ALK rearrangement.

A rare case report of a primary lung cancer comprising adenocarcinoma and atypical carcinoid tumor, with the carcinoid component harboring EML4-ALK rearrangement.

Journal: Translational lung cancer research

Published: April 21, 2024

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial.

Avelumab in Combination With Lorlatinib or Crizotinib in Patients With Previously Treated Advanced NSCLC: Phase 1b/2 Results From the JAVELIN Lung 101 Trial.

Journal: JTO clinical and research reports

Published: March 04, 2024

Antibody-drug conjugate development: opening windows for EGFR-mutant EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancers?

Antibody-drug conjugate development: opening windows for EGFR-mutant EGFR tyrosine kinase inhibitor-resistant non-small cell lung cancers?

Journal: Translational lung cancer research

Published: January 29, 2024

Downregulation of homeobox B8 in attenuating non-small cell lung cancer cell migration and invasion though the epithelial-mesenchymal transition pathway.

Downregulation of homeobox B8 in attenuating non-small cell lung cancer cell migration and invasion though the epithelial-mesenchymal transition pathway.

Journal: Translational cancer research

Published: December 21, 2023

PD-1-induced encephalopathy: a report of 2 cases on neurological toxicities with immune checkpoint inhibitors.

PD-1-induced encephalopathy: a report of 2 cases on neurological toxicities with immune checkpoint inhibitors.

Journal: Translational cancer research

Published: November 03, 2023

Showing 1-12 of 163

Last Updated: 09/26/2026